The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
Open accessAbstract
Adjuvant therapy is one of the major advances in the treatment of breast carcinoma patients - but do all patients need it? New predictive markers, which are able to save breast carcinoma patients from the most toxic adjuvant therapies, are still needed. The expression of matrix metalloproteinases (MMP-2) has been previously linked to invasiveness of carcinoma cells. In this study, we explored the role of MMP-2 as a prognostic factor in breast carcinoma in a large series to be able to show the favourable effect of MMP-2 negativity in poor prognosis subgroup of hormone receptor-negative patients. The MMP-2 immunoreactive protein was evaluated from primary adenocarcinoma of the breast in 453 cases by using a specific monoclonal antibody in immunohistochemical stainings. The MMP-2 protein found in breast carcinoma tumour cells was here shown to be associated with a shortened recurrence-free survival or relative overall survival (P=0.03). It was shown here that MMP-2 negativity is significantly linked to favourable prognosis in patients considered to be at risk due to their hormone receptor negativity. In the patient group presenting with a progesterone receptor-negative tumour, the survival rate of the MMP-2-positive cases was 58% while it was 95% in MMP-2-negative cases after 10 years of follow-up (P=0.005). The present data shows for the first time that MMP-2 negativity could serve as a marker for favourable prognosis in breast carcinoma patients with a hormone receptor-negative tumour usually associated with high risk. MMP-2 is also shown to correlate to shortened survival independent of major prognostic indicators in patients with primary breast carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Cited by
Biochemical and Biological Attributes of Matrix Metalloproteinases
Cui, N., Hu, M., & Khalil, R. A. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.02.005 · Cited by 1,359
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., & Tsien, R. Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408191101 · Cited by 822
Beyond the margins: real-time detection of cancer using targeted fluorophores
Zhang, R. R., Schroeder, A. B., Grudzinski, J. J., Rosenthal, E. L., Warram, J. M., Pinchuk, A. N., Eliceiri, K. W., Kuo, J. S., & Weichert, J. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.212 · Cited by 485
Pellikainen, J. M., Ropponen, K. M., Kataja, V. V., Kellokoski, J. K., Eskelinen, M. J., & Kosma, V.-M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1061 · Cited by 339
Molecular imaging for cancer diagnosis and surgery
Hussain, T., & Nguyen, Q. T. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.007 · Cited by 337
Metadata
- Authors
- Talvensaari-Mattila, A., Pääkkö, P., & Turpeenniemi-Hujanen, T.
- Venue
- British Journal of Cancer
- Published
- 2003-09-30
- Volume
- 89
- Issue
- 7
- Pages
- 1270-1275
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2088422531
- Cited by
- 217
- References
- 1
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6601238
- The paper
- Talvensaari-Mattila, A., Pääkkö, P., & Turpeenniemi-Hujanen, T. (2003). Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6601238
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.